<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Meibomian gland dysfunction (MGD) results in the increased tear film osmolarity and leads to the development of dry eye disease. Results obtained in several experimental and clinical studies suggested that mesenchymal stem cells (MSCs) could promote repair and regeneration of injured meibomian glands. We recently developed a new biological product “derived-Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS)” which activity was based on the effects of immunosuppressive and trophic factors secreted by MSCs. Herewith, we report a case of MGD treated by d-MAPPS containing eye drops, demonstrating therapeutic potential of d-MAPPS in regeneration of injured meibomian glands and in the attenuation of MGD. D-MAPPS containing eye drops significantly attenuated MGD-related symptoms (foreign body sensation, burning, pain in the eye and eye fatigue) and remarkably improved quality of life. The analysis of meibomian glands demonstrated restoration of meibomian gland morphology, structure and function, after the 3-weeks of d-MAPPS based therapy. MGD patient did not report any adverse effects related to the d- MAPPS administration, indicating that d-MAPPS containing eye drops were safe for intraocular application.</p>
</abstract>

Meibomian gland dysfunction (MGD) results in the increased tear film osmolarity and leads to the development of dry eye disease. Results obtained in several experimental and clinical studies suggested that mesenchymal stem cells (MSCs) could promote repair and regeneration of injured meibomian glands. We recently developed a new biological product “derived-Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS)” which activity was based on the effects of immunosuppressive and trophic factors secreted by MSCs. Herewith, we report a case of MGD treated by d-MAPPS containing eye drops, demonstrating therapeutic potential of d-MAPPS in regeneration of injured meibomian glands and in the attenuation of MGD. D-MAPPS containing eye drops significantly attenuated MGD-related symptoms (foreign body sensation, burning, pain in the eye and eye fatigue) and remarkably improved quality of life. The analysis of meibomian glands demonstrated restoration of meibomian gland morphology, structure and function, after the 3-weeks of d-MAPPS based therapy. MGD patient did not report any adverse effects related to the d- MAPPS administration, indicating that d-MAPPS containing eye drops were safe for intraocular application.

Restoration of Meibomian Gland Functionality with Novel Mesenchymal Stem Cell-Derived Product “Derived-Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS)”: A Case Report

University of Kragujevac, Faculty of Medical Sciences

Department for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research

Experimental and Applied Biomedical Research (EABR)

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Meibomian gland dysfunction (MGD) results in the increased tear film osmolarity and leads to the development of dry eye disease. Results obtained in several...

Restoration of Meibomian Gland Functionality with Novel Mesenchymal Stem Cell-Derived Product “Derived-Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS)”: A Case Report

Pubblicato online: 20 giu 2023

Pagine: 169 - 174

Ricevuto: 24 feb 2020

Accettato: 17 mar 2020

DOI: https://doi.org/10.2478/sjecr-2020-0059

Parole chiave
Meibomian gland dysfunction, therapy, mesenchymal stem cells, d-MAPPS

© 2023 Carl Randall Harrell et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Restoration of Meibomian Gland Functionality with Novel Mesenchymal Stem Cell-Derived Product “Derived-Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS)”: A Case Report

Pubblicato online: 20 giu 2023

Pagine: 169 - 174

Ricevuto: 24 feb 2020

Accettato: 17 mar 2020

DOI: https://doi.org/10.2478/sjecr-2020-0059

Parole chiaveMeibomian gland dysfunction, therapy, mesenchymal stem cells, d-MAPPS

© 2023 Carl Randall Harrell et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Parole chiave
Meibomian gland dysfunction, therapy, mesenchymal stem cells, d-MAPPS